Announcements Trials

Browse Landscape

Phase

Phase 1 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 8 Genitourinary 2 Thoracic 1 Sarcoma 1 Other hematologic neoplasm 1 Dermatologic 1

Conditions

Metatropic dwarfism 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 551 Pemetrexed 404 Cisplatin 401 Paclitaxel 273 Docetaxel 255 Gemcitabine 218 pembrolizumab 191 Bevacizumab 190 Erlotinib Hydrochloride 184 Radiotherapy 181 Etoposide 147 durvalumab 140 Nivolumab 134 Drug Therapy 127 osimertinib 107 atezolizumab 92 Gefitinib 74 Radiosurgery 72 anlotinib 69 Vinorelbine 68 tislelizumab 52 Irinotecan 51 Ipilimumab 50 130-nm albumin-bound paclitaxel 50 Taxes 48 Surgical Procedures, Operative 46 Cetuximab 46 sintilimab 45 Albumin-Bound Paclitaxel 45 apatinib 44

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Cilengitide × Thoracic × Clear all

NCT00842712 2017-01-13

CERTO

Merck KGaA, Darmstadt, Germany

Phase 2 Completed

232 enrolled 17 charts

Metatropic dwarfism, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡